An endogenous inactivating inward-rectifying potassium current in oocytes of Xenopus laevis.
An endogenous inward-rectifying K+ current is described, which is present in native oocytes of some Xenopus laevis donors. Experiments were performed using defolliculated oocytes from donor frogs obtained from two different suppliers. In all oocytes from animals from one source, an inward-rectifying K+ current could be elicited with negative pulses from a holding potential of -20 mV in external solutions with a high K+ concentration. Increasing external K+ concentrations increased the amplitude of this current and shifted the reversal potential towards more positive potentials. In 118 mM KCl, the inward-rectifying K+ current partially inactivated between -20 and -80 mV and completely inactivated at more negative membrane potentials; 50% steady-state inactivation occurred near -50 mV. The time course of inactivation of the inward-rectifying current could be well fitted with two exponentials. The slow time constant had values of about 500 ms and was voltage independent. In contrast, the fast time constant and the time to reach the peak inward current decreased with more negative membrane potentials. Ba2+, Cs+, quinine (all 5 mM) and 50 mM tetraethylammonium partially blocked the inward-rectifying K+ current, whereas 10 mM 4-aminopyridine was without blocking effect. The oxidant chloramine-T blocked the inward-rectifying K+ current without slowing its inactivation.
Bauer
C K
CK
Physiologisches Institut, Universitätskrankenhaus Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Falk
T
T
Schwarz
J R
JR
D000818:Animals; D001464:Barium / Q000494:pharmacology; D002586:Cesium / Q000494:pharmacology; D002700:Chloramines / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D008564:Membrane Potentials / Q000187:drug effects; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism*; D011188:Potassium / Q000378:metabolism*; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism*; D011189:Potassium Chloride / Q000494:pharmacology; D011803:Quinine / Q000494:pharmacology; D017337:Sermorelin / Q000031:analogs & derivatives / Q000494:pharmacology; D012964:Sodium / Q000378:metabolism; D014105:Tosyl Compounds / Q000494:pharmacology; D014982:Xenopus laevis
D002700:Chloramines; D006727:Hormone Antagonists; D015221:Potassium Channels; D014105:Tosyl Compounds; C016300:chloramine-T; D002586:Cesium; D001464:Barium; D011189:Potassium Chloride; D017337:Sermorelin; C045616:somatotropin releasing hormone (1-29)-amide, N-Ac-Tyr(1)-Phe(2)-; D012964:Sodium; D011803:Quinine; D000242:Cyclic AMP; D011188:Potassium